Email this article ANALYSIS OF BIOLOGICAL PROPERTIES OF STRAINS-PRODUCERS OF A NUMBER OFPSEUDOMONAS AERUGINOSA RECOMBINANT PROTEINS
- Authors: Soldatenkova AV1, Leonova EI1, Zlygostev SA1, Mikhaylova NA1, Soldatenkova AV2, Leonova EI2, Zlygostev SA2, Mikhaylova NA2
-
Affiliations:
- Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia
- Issue: Vol 89, No 6 (2012)
- Pages: 60-64
- Section: Articles
- Submitted: 09.06.2023
- Published: 15.12.2012
- URL: https://microbiol.crie.ru/jour/article/view/13727
- ID: 13727
Cite item
Full Text
Abstract
proteins compared with the initial strains. Materials and methods. 5 Escherichia coli strains (initial
strains E. сoli M15 and E. сoli BL21(DE3) and strains-producers of OprL, OprF, aTox3 recombinant proteins
(E. coli М15/oprF, E. coli М15/oprL, E. coli BL21-аTox3) were studied. Toxicity, toxigenicity and virulence
determination were carried out in experiments in non-linear mice. Enzymatic properties of the initial strains
and strains-producers were compared in a number of biochemical tests. Results. The studied strains-producers
of the most immunogenic P. aeruginosa recombinant proteins were confirmed to be biosafe, belong to
Enterobacteriaceae family and Escherichia genus. As a result of genetic engineering manipulations carried out
with E. coli М15 and E. coli BL21(DE3) alterations of biochemical and growth properties, virulence, to xicity
and toxigenicity in the constructed strains-producers of recombinant proteins - E. coli М15/oprF, E. coli
М15/oprL, E. coli BL21-аTox3 - were not detected. Conclusion. The results obtained allow to consider the
possibility of use of E. coli М15/oprF, E. coli М15/oprL and E. coli BL21-аTox3 strains-producers for production
and isolation of candidate proteins for inclusion into vaccine against pseudomonas infection.
About the authors
A V Soldatenkova
E I Leonova
S A Zlygostev
N A Mikhaylova
A V Soldatenkova
Mechnikov Research Institute of Vaccines and Sera, Moscow, RussiaMechnikov Research Institute of Vaccines and Sera, Moscow, Russia
E I Leonova
Mechnikov Research Institute of Vaccines and Sera, Moscow, RussiaMechnikov Research Institute of Vaccines and Sera, Moscow, Russia
S A Zlygostev
Mechnikov Research Institute of Vaccines and Sera, Moscow, RussiaMechnikov Research Institute of Vaccines and Sera, Moscow, Russia
N A Mikhaylova
Mechnikov Research Institute of Vaccines and Sera, Moscow, RussiaMechnikov Research Institute of Vaccines and Sera, Moscow, Russia
References
- Беляков В.Д., Ряпис Л.А., Илюхин В.И. Псевдомонады и псевдомонозы. М., Медицина. 1990.
- Гатыпова Е.В., Злыгостев С.А., Калошин А.А., Михайлова Н.А. Исследование иммунобиологических свойств рекомбинантного белка OprL наружной мембраны Pseudomonas aeruginosa. Вестн. РАМН. 2009, 4: 25-28.
- Исаков М.А., Солдатенкова А.В., Калошин А.А., Михайлова Н.А. Изучение иммунобиологических свойств рекомбинантных атоксичных форм экзотоксина А Pseudomonas aeruginosa. Журн. микробиол. 2011, 2: 37-42.
- Нозокомиальные инфекции. Практическое руководство по антиинфекционной химиотерапии. Л.С.Страчунский, Ю.Б.Белоусов, С.Н.Козлов (ред.). М., 2002.
- Сидоренко С.В., Резван С.П., Стерхова Г.А., Грудинина С.А. Госпитальные инфекции, вызванные Pseudomonas aeruginosa. Распространение и клиническое значение антибиотикорезистентности. Антибиот. химиотерап. 1999, 44 (3): 25-33.
- Станиславский Е.С. Бактериальные структуры и их антигенность. М., Медицина, 1961.
- Doring G., Pier G.B. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine. 2008, 26 (8): 1011-1024.
- Hancock R.E., Siehnel R., Martin N. Outer membrane proteins of Pseudomonas. Mol. Microbiol. 1990, 4 (7): 1069-1075.
- Iglewski B.H., Kabat D. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc. Natl. Acad. Sci. USA. 1975, 72 (6): 2284-2288.
- Kaloshin A.A., Gatypova E.V., Mikhailova N.A. Obtaining recombinant forms of outer membrane protein F (OprF) of Pseudomonas aeruginosa and assessment of their immunogenic properties. Appl. Biochem. Microbiol. 2011, 47 (8): 780-788.
Supplementary files
